Shares of Guardant Health (GH) rose after the US Food and Drug Administration approved the company’s blood test to screen for colorectal cancer in some adults. It’s the first such test to get approval.
Market Domination anchors Julie Hyman and Josh Lipton discuss the approval in the video above.
For more expert insight and the latest market action, click here to watch this full episode of Market Domination.
This post was written by Stephanie Mikulich.
Source Agencies
